Pulmonary sarcoidosis induced by the anti-PD1 monoclonal antibody pembrolizumab

被引：64
|
作者：
Cousin, S. [1 ,2 ]
Toulmonde, M. [1 ,2 ]
Kind, M. [3 ]
Cazeau, A. -L. [4 ]
Bechade, D. [2 ]
Coindre, J. -M. [5 ]
Italiano, A. [1 ,2 ]
机构：
[1] Inst Bergonie, Early Phase Trials Unit, Bordeaux, France
[2] Inst Bergonie, Dept Med, Bordeaux, France
[3] Inst Bergonie, Dept Radiol, Bordeaux, France
[4] Inst Bergonie, Dept Nucl Med, Bordeaux, France
[5] Inst Bergonie, Dept Pathol, Bordeaux, France
来源：
ANNALS OF ONCOLOGY | 2016年 / 27卷 / 06期
关键词：
METASTATIC MELANOMA; IPILIMUMAB; PATIENT;
D O I：
10.1093/annonc/mdw125
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1178 / 1179
页数：2
相关论文
共 50 条
  • [1] Pulmonary sarcoidosis or post-immunotherapy granulomatous reaction induced by the anti-PD-1 monoclonal antibody pembrolizumab: the terminology is not the key point
    Cousin, S.
    Italiano, A.
    ANNALS OF ONCOLOGY, 2016, 27 (10) : 1974 - 1975
  • [2] Metastatic site and response to pembrolizumab (anti-PD1 antibody) in melanoma
    Tumeh, Paul Camille
    Rosenblum, Michael
    Handley, Nathan
    Tsai, Katy
    Rodriguez, Robert S. Rodriguez
    Khurana, Niharika
    Harview, Christina
    Spasic, Marko
    Sanchez, Phillip J.
    Chang, Jeremy
    Shintaku, I. Peter
    Taylor, Emma
    Chmielowski, Bartosz
    Grogan, Tristan
    Elashoff, David A.
    Pierce, Robert H.
    Daud, Adil
    CANCER RESEARCH, 2015, 75
  • [3] Pulmonary sarcoidosis induced by the anti-PD-1 monoclonal antibody pembrolizumab or post-immunotherapy granulomatous reaction: which is more appropriate terminology?
    Paydas, S.
    ANNALS OF ONCOLOGY, 2016, 27 (08) : 1650 - 1651
  • [4] Arthritis and Tenosynovitis Associated With the Anti-PD1 Antibody Pembrolizumab in Metastatic Melanoma
    Chan, Matthew M. K.
    Kefford, Richard F.
    Carlino, Matteo
    Clements, Arthur
    Manoliosz, Nicholas
    JOURNAL OF IMMUNOTHERAPY, 2015, 38 (01) : 37 - 39
  • [5] The Effects of Brain Metastases in Melanoma Patients on anti-PD1 Antibody Therapy with Pembrolizumab
    Weichenthal, M.
    Mohr, P.
    Leiter-Stoeppke, U.
    Ugurel, S.
    Kaehler, K.
    Gutzmer, R.
    Pfoehler, C.
    Hassel, J. C.
    Nashan, D.
    Terheyden, P.
    Schell, B.
    Utikal, J. S.
    Kreuter, A.
    Haferkamp, S.
    Kaune, K.
    Berking, C.
    Debus, D.
    Ulrich, J.
    Dabrowski, E.
    Eigentler, T.
    Welzel, J.
    Herbst, R.
    Loquai, C.
    Meier, F.
    Schadendorf, D.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2021, 19 : 5 - 6
  • [6] A case of severe neuro-Sjogren induced by Pembrolizumab (anti-PD1)
    Ghosn, J.
    Obeid, M.
    Spertini, F.
    SWISS MEDICAL WEEKLY, 2018, 148 : 35S - 35S
  • [7] Anti-PD1 Antibody Treatment and the Development of Acute Pulmonary Tuberculosis
    Fujita, Kohei
    Terashima, Tsuyoshi
    Mio, Tadashi
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (12) : 2238 - 2240
  • [8] Caffeine-enhanced anti-tumor activity of anti-PD1 monoclonal antibody
    Tej, Gullanki Naga Venkata Charan
    Neogi, Kaushik
    Nayak, Prasanta Kumar
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2019, 77
  • [9] Review of the Combination Strategies Used in Anti-PD1/PD-L1 Monoclonal Antibody Treatment
    Cheng, Jiaxing
    2020 INTERNATIONAL CONFERENCE ON ENERGY, ENVIRONMENT AND BIOENGINEERING (ICEEB 2020), 2020, 185
  • [10] Anti-PD1 Antibody Pembrolizumab treatment of Metastatic Thymic Cancer as Antigenic Trigger for Myasthenia Gravis
    Baten, Ahmareen
    Yusuf, Nadia
    Tornatore, Carlo
    NEUROLOGY, 2017, 88
12345